These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 30429036)
1. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036 [TBL] [Abstract][Full Text] [Related]
2. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma. Yokoyama S; Miyoshi H; Nishi T; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Kakuma T; Ohshima K Ann Thorac Surg; 2016 Apr; 101(4):1361-9. PubMed ID: 26794891 [TBL] [Abstract][Full Text] [Related]
5. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286 [TBL] [Abstract][Full Text] [Related]
6. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Zhang L; Wang XI; Ding J; Sun Q; Zhang S Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176 [TBL] [Abstract][Full Text] [Related]
7. Impact of sidedness of colorectal cancer on tumor immunity. Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001 [TBL] [Abstract][Full Text] [Related]
8. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature. Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1. Hakiri S; Fukui T; Mori S; Kawaguchi K; Nakamura S; Ozeki N; Kato T; Goto M; Yatabe Y; Yokoi K Ann Thorac Surg; 2019 Feb; 107(2):418-424. PubMed ID: 30312607 [TBL] [Abstract][Full Text] [Related]
10. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912 [TBL] [Abstract][Full Text] [Related]
11. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study. Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744 [TBL] [Abstract][Full Text] [Related]
12. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549 [TBL] [Abstract][Full Text] [Related]
13. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis. Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566 [TBL] [Abstract][Full Text] [Related]
14. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer. Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866 [TBL] [Abstract][Full Text] [Related]
15. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma]. Liu HQ; Zou BQ; Wang SY Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692 [No Abstract] [Full Text] [Related]
16. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603 [TBL] [Abstract][Full Text] [Related]
17. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis. Chen HF; Wu LX; Li XF; Zhu YC; Pan WW; Wang WX; Xu CW; Huang JH; Wu MH; Du KQ Tumori; 2020 Aug; 106(4):306-311. PubMed ID: 32366210 [TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Li F; Zhao Y; Wei L; Li S; Liu J Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426 [TBL] [Abstract][Full Text] [Related]
20. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]